Amendola, a nationally recognized, award-winning healthcare technology and life sciences public relations and marketing firm, today announced that it has been selected to implement a national PR program by Peerbridge Health, developer of a hospital-grade, remote diagnostic and monitoring platform that harnesses artificial intelligence (AI) for early detection of heart failure and other conditions.
“Amendola comes highly recommended by healthcare technology peers, giving us confidence that its industry-specific expertise and successful track record will produce valuable results,” said Chris Darland, CEO of Peerbridge Health. “We look forward to working with Amendola to educate the industry on the life-saving potential of early detection of heart failure through AI-enabled remote monitoring technology, which we are able to offer at a significantly lower cost compared to traditional methods.”
More than 6 million Americans live with heart failure, and each year around 1 million new cases are diagnosed in adults 55 years of age and over. Heart failure is the second-leading cause of hospitalization in the U.S. and the leading cause of hospitalization among adults 65 and older.
To reduce the impact of heart failure, Peerbridge Health has developed the Peerbridge Cor™, an AI-enabled, 3-lead, 2-channel wireless ambulatory ECG device. A recent feasibility trial showed the device had a nearly 96% accuracy rate in identifying heart failure in patients utilizing ECG as the only input.
“Heart failure is a serious condition that is often only diagnosed after a visit to the emergency room,” said agency CEO Jodi Amendola. “We are pleased to partner with Peerbridge Health in its efforts to extend access to care, improve outcomes for cardiac patients, and reduce the financial burden of this disease.”
For more such updates, follow us on Google News Martech News